PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBSSESIVE-COMPULSIVE SPECTRUM DISORDER CAUSED BY NINJURIN 1 DEFICIENCY

摘要

The present invention relates to a pharmaceutical composition for treating or preventing obsessive compulsive disorder including the antagonist of N-Methyl-D-aspartate (NMDA) receptor as an active ingredient. More specifically, in the present invention, provided is a pharmaceutical composition for treating and/or preventing the obsessive compulsive disorder caused by Ninjurin 1 deficiency by using memantine or pharmaceutically acceptable salts thereof. According to the present invention, a Ninjurin 1 KO mouse is offered to study the obsessive compulsive disorder as a new model, and memantine which is the antagonist of the NMDA receptor or pharmaceutically acceptable salts thereof is offered and used to newly treat the obsessive compulsive disorder.